MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

View Full Size 

Download

• Full Size JPEG, 837x703, 160.5 KB
• Small JPEG, 480x403, 80.7 KB
• Preview JPEG, 144x121, 15.9 KB
• Thumbnail JPEG, 83x70, 7.2 KB